FTC sues main pharmacy benefit managers over insulin price ranges The company brought action in opposition to Caremark, Specific Scripts and Optum Rx, arguing their “anticompetitive and unfair” rebating methods “artificially inflated” the list price of daily life-conserving insulin medicine. You should not miss out on tomorrow's healthcare business news https://kethek.com/